argenx to Present at 44th Annual J.P. Morgan Healthcare Conference

argenx SE (Euronext & Nasdaq: ARGX), a global immunology company focused on improving the lives of people with severe autoimmune diseases, announced on January 6, 2026 that its Chief Executive Officer, Tim Van Hauwermeiren, will present at the 44th Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for Monday, January 12, 2026 at 8:15 a.m. Pacific Time in San Francisco. A live webcast of the presentation will be available via the Investors section of the argenx website, and a replay will be accessible on the site for approximately 30 days following the event. Founded in Amsterdam, argenx is committed to translating immunology breakthroughs into a leading portfolio of novel antibody‑based medicines in collaboration with academic researchers through its Immunology Innovation Program (IIP). The company has developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its potential across multiple serious autoimmune diseases, while advancing other experimental medicines in its therapeutic franchises. For more details or media inquiries, contacts include Ben Petok for media and Alexandra Roy for investors. #argenx #JPMHealthcareConference #Immunology #BiotechNews #SlimScan #GrowthStocks #CANSLIM